One major aim of preclinical intracerebral hemorrhage (ICH) research is to develop and test
potential neuroprotectants. Published guidelines for experimental design and reporting …

The likelihood of translating therapeutic interventions for stroke rests on the quality of
preclinical science. Given the limited success of putative treatments for ischemic stroke and …

Intracerebral hemorrhage (ICH) has the highest mortality of all stroke subtypes, yet
treatments are mainly limited to supportive management, and surgery remains controversial …

The collagenase and whole blood intracerebral hemorrhage (ICH) models are widely used
to identify mechanisms of injury and to evaluate treatments. Despite preclinical successes, to …

Intracerebral hemorrhage is a devastating neurological illness with few treatment options. In
the past 10 years, 6 clinical trials have been completed examining the potential role that …

The most deadly form of stroke, intracerebral hemorrhage (ICH) continues to puzzle
researchers and produce substantial decrements in the quality of patients' lives. Intensive …

Importance Preclinical stroke research has had a remarkably low translational success rate,
and the clinical need for novel neuroprotective therapeutics has gone largely unmet …

Many therapies have shown promise in preclinical stroke studies, but few benefit patients. A
greater understanding of stroke pathophysiology is needed to successfully develop …

The discrepancy in results regarding neuroprotective agents in animal experiments
compared to clinical trials is a major problem. While many neuroprotective agents have …

Our increased understanding of the ischaemic cascade has driven the rush to develop
neuroprotective interventions. Over 500 have been reported to effectively improve outcome …